Showing 11-20 of 105 results for "".
Board forum: What’s Next for Aesthetic Practice?
https://modernaesthetics.com/ma-issues-index/2020-nov-dec/board-forum-whats-next-for-aesthetic-practice/34974/Experts weigh in on the short- and long-term prognosis for the field.Board Forum: Managing Overhead
https://modernaesthetics.com/topics/practice-development/board-forum-managing-overhead/35132/What's Next in Aesthetic Medicine?
https://modernaesthetics.com/ma-issues-index/2018-jan-feb/cosmetic-surgery-outlook/34180/Insights on the future of cosmetic care.- The Newest Xeomin Brand Partner is Joe Jonashttps://modernaesthetics.com/news/the-newest-xeomin-brand-partner-is-joe-jonas/2473280/Joe Jonas is the latest Xeomin (incobotulinumtoxinA) brand partner, Merz Aesthetics announced. The U.S. partnership with Jonas kicks off a new ‘Beauty on Your Terms’ campaign for Xeomin and represents the first time the singer, songwriter and actor has pa
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Crown Laboratories, Inc.'s Announces Leadership Team Growthhttps://modernaesthetics.com/news/crown-laboratories-incs-annouces-leadership-team-growth/2473256/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- GALDA Co-Director Explains Organization's Work and Impacthttps://modernaesthetics.com/news/galda-co-director-explains-organizations-work-and-impact/2475382/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://modernaesthetics.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2475357/Key Takeaways Individuals aged 18–39 make up two-thirds of those seeking tattoo removal, with visible areas such as forearms and hands being the most treated. Black ink remains the most commonly removed tattoo pigment. Fitzpatrick Skin Types III and
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea